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Abstract 
Introduction and Aims: Opioid overdose can be reversed with timely administration of 
naloxone. In Australia, naloxone was rescheduled from prescription only (S4) to 
pharmacist only over-the-counter (OTC, S3) in February 2016, increasing access for the 
general public. A key barrier to naloxone supply by pharmacists is a lack of knowledge, 
highlighting the role of pharmacist education. Community pharmacists’ education, 
experience, and training preferences related to naloxone provision, overdose, and 
substance use disorder were examined. 
Methods: Online survey data from a national sample of Australian pharmacists on their 
educational preferences regarding naloxone and overdose prevention, and prior training on 
substance use disorder (n = 595) was analyzed using bivariate and multivariate regression 
analysis. Data from qualitative semi-structured telephone interviews with pharmacists 
about OTC naloxone provision (n=21) was analyzed using thematic analysis.  
Results: Most pharmacists (81%, n = 479) were willing to be trained in opioid overdose 
prevention, with greater willingness to attend training associated with younger age, being 
female, fewer years of practice, not having attended previous education on substance use 
disorder, and higher confidence in issues relating to substance use disorder. Qualitative 
interviews confirmed community pharmacists’ willingness to attend training but analysis 
revealed low awareness, knowledge, and confidence about naloxone and preventing opioid 
overdose. Most pharmacists preferred online training or webinars. 
Discussion and Conclusion: Most community pharmacists in Australia are willing to 
attend training on providing naloxone and preventing opioid overdose. There are 
opportunities to develop and expand the online presence of training, guidelines, and 
education materials to facilitate the expanded supply of OTC naloxone.    
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Introduction  
Deaths from opioid overdose are increasing, yet opioid overdose can be reversed with 
timely administration of naloxone (1, 2).  Naloxone is recommended to be widely 
available by the World Health Organization (3), with the intention that it is administered at 
a later time by a trained layperson who witnesses an overdose (also known as ‘take-home’ 
naloxone, or THN).  Internationally, pharmacists are recognized as potential educators and 
distributers of naloxone to the community (4, 5) but few countries are yet to widely 
distribute naloxone in this setting. According to available literature only Italy, Australia 
and some US states have naloxone available without a prescription (1). To maximize 
naloxone availability through pharmacies the experiences and attitudes of pharmacists on 
their new roles as distributers of naloxone in the community need to be better understood.  
In February 2016 in Australia, naloxone was rescheduled from prescription only (S4) to 
pharmacist only over the counter (OTC, S3) (1), yet OTC naloxone has not been widely 
taken up by community pharmacies. Previously in Australia, patients needed a prescription 
from their general practitioner either via traditional medical appointments, or though 
attendance at a specialised overdose prevention training workshop (1, 6). The rescheduling 
required a change to the Standard for the Uniform Scheduling of Medicines and Poisons 
legislation administered by the Australian Therapeutic Goods Administration (TGA) in 
order to ‘down‐schedule’ naloxone from its existing Schedule 4 status as a ‘prescription 
only’ medicine to a ‘pharmacist only’ (Schedule 3) medicine. Schedule 3, or OTC 
medicines, are stored behind the counter and a pharmacist must be involved in the sale to 
ensure safe use of medicines. The down‐scheduling enables pharmacists to initiate 
naloxone supply and allows members of the public to request naloxone from pharmacies. 
In Australia, opioid overdose deaths have increased each year since 2006, with a 64% 
increase in overdose deaths in the ten years leading up to 2015 (9). On a global level, 
Australia has a higher than average drug mortality rate with opioids being the leading 
cause of drug-related death (10). In most cases, these deaths are accidental and preventable 
and population level responses are required to reverse these concerning trends. The 
rescheduling of naloxone in Australia recognises the potential role of pharmacists in 
overdose prevention including as educators and distributers of naloxone (4, 5, 11, 12).  
A scoping review and Australian national online survey of pharmacists completed in 2015 
revealed that community pharmacists hold positive attitudes towards provision of illicit 
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drug-related harm reduction services, including naloxone supply (7, 8). Yet few 
pharmacists appear confident in their ability to identify and train patients in administering 
OTC naloxone (8). Furthermore, many pharmacists have limited knowledge of naloxone, 
highlighting the importance of education in this area (8). 
To better understand the educational needs and preferences of pharmacists around 
naloxone supply a mixed-methods study (online survey and qualitative interviews) of 
community pharmacists’ preferences for provision of naloxone to people at risk of opioid 
overdose, their family, and friends was conducted. To gain further insight into the findings 
from the online survey data, qualitative interviews examined pharmacists’ behaviors and 
preferences for opioid overdose prevention training, and explored facilitators and barriers 
to training on OTC naloxone. Three questions were addressed: 
1. How does previous experience with substance use disorder (SUD) training and 
treatment provision influence current (i) confidence and (ii) willingness to supply 
naloxone? 
2. What factors influence pharmacist’s willingness to participate in opioid overdose 
prevention training?  
3. What are pharmacists’ preferences for training delivery? 
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Methods 
Using a sequential explanatory mixed methods design (13), community pharmacists’ 
education needs in relation to naloxone and overdose prevention was investigated using 
two data sources: 
1. Quantitative data from an existing national online survey (n = 595); and 
2. Qualitative telephone interviews with a sample of those who participated in the 
national online survey (n=21). 
Qualitative data were used to explore, in greater depth, findings from the quantitative 
national survey, providing validation of key findings and context to the survey results (14). 
National online survey 
Previously unreported data from a national online survey undertaken in September–
November 2015 (8) was analyzed. This study aimed to recruit a nationally representative 
sample of 10% of community pharmacies. Pharmacies were contacted by phone with the 
pharmacist-in-charge or pharmacist manager invited to participate, with a request to 
provide an email address. We sought to have one pharmacist (the pharmacist in charge) to 
represent the situation in each pharmacy to avoid multiple responses per pharmacy. Where 
pharmacists were willing to receive further information, an invitation email was sent 
which included a link to the participant information statement and online survey. With a 
response rate of 45%, 595 community pharmacists participated in the survey, representing 
11% of the 5,450 operating pharmacies in Australia (8) (see Figure 1 for recruitment 
flow). The online survey was designed to take fewer than 20 minutes to complete (mean 
completion time was 26.6 minutes, median 18.7 minutes). 
Pharmacists were reimbursed AUD$40 for completing the survey. This quantitative study 
was approved by the University of New South Wales Human Research Ethics Advisory 
(HREA) Panel: Social and Health Research (HC15556). 
 
Measures 
Four age groups (less than 25 years of age, 25-34 years old, 35-54 years and 55 years and 
above), gender, years of practice and further education about SUD after graduating were 
examined. All were examined as binary variables, except for years of practice which was 
examined as a continuous variable. 
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Geographic location was classified as capital city, other metropolitan urban center 
(population equal to or greater than 100,000), rural location (population between 5,000 to 
99,999) and remote area (population less than or equal to 5,000). Rural and remote 
categories were collapsed, as there were fewer respondents in these categories. 
Previous experience with SUD training and confidence to supply naloxone were examined 
as binary variables. Current provision of opioid substitution treatment (OST) and whether 
the pharmacy stocked naloxone were examined as binary variables.  
Confidence in ability to educate patients to recognize opioid overdose and safely 
administer naloxone was measured using a 7-point scale where 1 = “not at all confident” 
and 7 = “extremely confident”.  
Willingness to educate patients to recognize opioid overdose and safely administer 
naloxone, and to attend training were both rated by participants on a 4-point scale from 
“already doing this” to “not at all willing to do this”. Responses were collapsed into a 
binary variable where participants who were “already doing this activity” and “extremely 
willing to do this activity” formed one group, while “somewhat willing to do this” and 
“not at all willing to do this” formed the other. This was due to low response numbers in 
the outer most two options (n<10).    
Preferred format of training was examined. Seven options were offered: “face-to-face 
(one-to-one)”, “online”, “webinar”, “both online and face-to-face”, “would not like to 
receive training”, “face-to-face (group)” and “written”.  
The time willing to spend receiving education about naloxone was offered as six 
groupings: “less than 5 minutes”, “between 5-15 minutes”, “between 16-59 minutes” 
“between 1-2 hours”, “up to 4 hours”, and “more than 4 hours”.  
Data were descriptively analyzed to examine pharmacists’ previous continual professional 
education (CPD) and their willingness, time and preferences for training relating to OTC 
naloxone supply. Ordinal logistic regression was used to assess the associations with 
pharmacists confidence to educate patients in opioid overdose and administering naloxone. 
Multivariable logistic regression analyses were conducted with dependent variables: 
willingness to educate patients regarding opioid overdose and administering naloxone and 
willingness to participate in training.  Independent variables explored were OST provision, 
and previous SUD training, adjusting for pharmacists’ demographic characteristics, 
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confidence and experiences with naloxone. Pharmacists preferences around naloxone 
training were descriptively explored. All analyses were conducted using SPSS Version 23. 
 
Qualitative telephone interviews 
Pharmacists who had participated in the national survey who indicated interest in 
participating in further research were contacted by email and invited to participate in a 
short telephone interview, in addition to promoting the study through professional 
networks. 
We interviewed 21 community pharmacists from three states in Australia, Victoria (n=6), 
New South Wales (n=10) and Queensland (n=5). We purposively recruited for variation 
according to gender, age, geographic diversity as well as provision of harm reduction 
services. Around half (11 of 21) were female; six were aged 20-29 years, nine were 30-39 
years and six were aged over 40 years. Most (16 out of 21) were from metropolitan 
locations (as opposed to regional or rural), eight provided Needle Syringe Program (NSP) 
services, and 11 provided OST services.  
All procedures were approved by University of New South Wales HREA Panel G: Health, 
Medical, Community and Social (HC16598) and UQ School of Pharmacy Ethics 
Committee (Ref: 2016/7, #2016001381). 
Interviews were used to explore community pharmacists’ experiences of and attitudes to 
providing OTC naloxone. Topics included: the role of pharmacists supporting people at 
risk of opioid overdose; knowledge of and attitudes to OTC naloxone provision; and 
required information or training. This paper is focused on their accounts of naloxone 
training, willingness to receive future training, as well as training preferences. Pharmacists 
were interviewed over the telephone using a semi-structured interview guide. A brief 
survey was used to collect basic demographic information.  
Interviews took 30-45 minutes. Pharmacists chose whether to be reimbursed AUD$50 for 
their time and contribution to research or to donate AUD$50 to one of three charities. Data 
were collected between September 2016 and December 2016.  
Interviews were digitally recorded and professionally transcribed. Transcripts were de-
identified and data were analysed in NVivo 11 software using a thematic analysis 
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approach (14, 15). Preliminary analysis, including the development of a preliminary 
codebook, was conducted by author KLJC guided by the research questions above. 
Following the steps outlined by Braun and Clarke (15), coding and analysis of the full 
dataset was completed by author AO. Transcripts were read and re-read, comparing 
interviews for similarities and differences. Transcripts were then coded systematically to 
establish themes. This manuscript focusses on the findings relating to previous experiences 
of SUD training, confidence and willingness to supply naloxone, attitudes to training and 
preferences for training delivery.  
Please see supplementary material for full details of questions asked in the online survey 
and qualitative interviews. 
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Results  
Participant demographics. 
Table 1 displays the descriptive statistics for the survey participants. The 595 respondents 
were roughly split evenly between males and females (54% and 46%, respectively). 
Respondents had been practicing for a median of 9 years (IQR: 5-21 years) with 
approximately half receiving training on SUD after graduating (n=288, 48%) and currently 
providing OST services (n=307, 52%). Despite the majority of pharmacists having heard 
of naloxone being used in the community for opioid reversal (n=425, 71%), only around a 
quarter were aware of naloxone being stocked in their pharmacy (n=136, 23%). 
 
Associations with confidence and willingness to educate patients on opioid overdose 
and naloxone administration.   
The majority of survey participants were either already (n=10, 2%) or extremely willing 
(n=471, 76%) to educate patients on opioid overdose recognition and safe naloxone 
administration, while the median confidence level was average (4 out of 7), with two 
thirds (62%) of pharmacists falling between 3 and 5 (1 being ‘not at all confident’ and 7 
being ‘extremely confident”). Confidence was associated with gender (OR 1.91, 95%CI 
1.43, 2.57) with males being more confident than females (Table 2). Provision of OST 
services, number of years practicing and confidence to educate were all associated with 
willingness to educate patients on overdose risk (Table 3). Pharmacists already providing 
OST services were more willing (OR 1.65, 95%CI 1.07, 2.53) as were those who were 
confident to educate (OR 1.45, 95%CI 1.27, 1.67). Pharmacists who had been practicing 
for longer were less willing to educate patients in opioid overdose and naloxone 
administration (OR 0.97, 95%CI 0.95, 0.99). No association was found between previous 
education on SUD for either willingness or confidence, whilst OST provision had no effect 
on confidence. 
 
Pharmacists’ willingness to attend training on naloxone and overdose prevention  
Few pharmacists interviewed in the qualitative study had attended any naloxone specific 
training and most seemed unaware of resources or training available to assist them in 
providing OTC naloxone. This is illustrated in the following quotations. 
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I don’t really know much at all. I tried to have a look at the PSA 
[Pharmaceutical Society of Australia] guideline for OTC naloxone, but I’m 
not a member of PSA, so I couldn’t get the guidelines, otherwise I would 
have had a read of that to see what pharmacists can do. (Female, 30-39 
years, Regional Pharmacy NSW) 
I only receive the training how to do the opioid substitution program from 
my own boss, but I haven’t heard anything about naloxone actually from 
him. (Male, 20-29 years, Metro NSW) 
… because we don’t get asked for it [naloxone]. For us… I don’t really 
know because I haven’t done it [training]. (Female, 40-49 years, Remote 
NSW)  
Overall, most pharmacists who participated in the survey were extremely willing to attend 
(n=471, 79%) or had already completed training about naloxone (n=8, 1%). Analysis of 
the survey data shows that particular demographic characteristics were associated with 
their willingness to attend education on opioid overdose prevention (Table 4). Pharmacists 
who had had previous education on SUD were almost twice as willing to attend training 
(OR 1.94, 95%CI 1.23, 3.06) than those who had not. Males were half as likely to be 
willing attend (OR 0.44, 95%CI 0.28 , 0.70) than females.  
Each year of increased practice experience was associated with reduced odds of being 
willing to attend training (OR 0.96, 95% CI 0.95, 0.98). Pharmacists who were confident 
about educating patients in opioid overdose and administration of naloxone were 
significantly more willing to attend training (OR 1.31, 95% CI 1.14, 1.50). No association 
was found between willingness to attend training and current provision of OST or 
geographical location of pharmacy. 
While most pharmacists were willing to attend training on opioid overdose prevention or 
naloxone provision, some were reluctant.  Analysis of the qualitative interview data 
suggests that this may be, in part, because some pharmacists believe that people living 
with SUD are a problematic client group, and that naloxone provision is best provided in 
services specifically catering for people living with SUD rather than community 
pharmacies. The following quotations highlight these concerns. 
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See, the issue is like dealing with those types of people overdosing. I’m not 
trying to stereotype or anything, but … this type of people are not really 
easy to handle or to manage … I believe not every pharmacist is going to do 
it. So if we make it obligatory … we are obliging every pharmacist to 
manage or to handle this type of medical condition or this type of patients, 
which is not easy for every pharmacist or for every type of pharmacy. 
(Male, 40-49 years, Metro NSW) 
 I think if a patient is on an opioid replacement program, there should be 
some kind of educator in the methadone clinic or the doctor to explain the 
importance of [naloxone]… (Male, 20-29 years, Metro NSW) 
Despite these expressed concerns, qualitative interviews confirmed that most pharmacists 
were willing to attend training, and those already involved in OST were notably positive 
about extending harm reduction efforts to include naloxone supply.  
I mean, if you are willing to engage in the pharmacotherapy [OST] 
program, the hope is that you would be willing to engage in … harm 
minimization … it sort of goes hand in glove with what you are already 
doing. So you’d hope that it’s not too much of a burden. A lot of people 
engage in that sort of training anyway and it’s nice to keep the knowledge 
up. (Male, 20-29 years, Metro Victoria) 
Preferred mode of delivery for training 
More than two thirds of the survey respondents had a preference for between 5 and 59 
minutes (n=413 of 595, 69%), while fewer (n= 157 of 595, 26%) were willing to spend 
more than one hour on naloxone training (Table 5). Responses from interview participants 
on time willing to spend on naloxone training varied from less than five minutes to more 
than four hours. Pharmacists expressed availability constraints during working hours. 
Furthermore, they were reluctant to spend time on training unless the education session 
was counted towards their continuing personal development (CPD) points or there was a 
financial incentive associated with counselling and distribution of naloxone from 
pharmacies.  
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If it is a rep from a company, I would like to spend about 10-15 minutes with 
him, because basically that is the time that you need to counsel a patient 
with the naloxone too.  (Male, 20-29 years, Metro NSW) 
In terms of mode of delivery, most pharmacists completing the survey preferred 
online/webinar training (n = 328, 55%), or face-to-face training (n = 253, 45%). Fourteen 
(2%) participants did not express a preference between face-to-face or online training: 
three (<1%) indicated a preference to attend both online and face-to-face training, six (1%) 
preferred written training and five (<1%) did not wish to attend any training at all (Table 
4). In addition to their primary choice of training delivery, 32 respondents provided 
additional comments. The most common comment cited additional or multiple preferences 
(n=19), 6 stated face to face would be ideal but is often impractical (especially for rural 
pharmacists), 4 suggested supplementary written or online material for later review and 3 
highlighted the importance for interactive sessions/ ability to ask questions.  
Responses from interview participants on preferred mode of delivery also varied. Some 
indicated that they engaged in self-learning (such as reading articles and guidelines and 
watching webinars), others expressed desire for structured training activities (such as 
formal workshops and training modules), while still others noted a lack of time and 
preference for short demonstration training (such as short one-on-one demonstrations from 
drug company representatives or online videos). The following quotations illustrate the 
diversity of training preferences. 
A video would be nice to watch at home in your free time and it’s flexible.  
(Female 20-29 years, Metro NSW) 
Journals are also good, because we can read in our spare time. (Female 20-
29 years, Metro NSW) 
I don’t really have a lot of time to get to face to face training so … I don’t 
mind online and ideally when you are looking at a case study and an 
interaction like actually seeing a video of different examples of appropriate 
or inappropriate ways to go about it. (Male 30-39 years, Metro Victoria)  
Most suggested that the Pharmacy Guild, PSA and/or pharmaceutical companies were 
possible or preferred providers of the education.  
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I would like the PSA and the Guild to actually get behind it and actually do 
some training. (Male 50-59 years, Regional NSW)  
I prefer if there is a representative from naloxone company to visit the 
pharmacies to give some education that will be awesome. (Male 20-29 
years, Metro NSW)  
Leaflets with diagrams and videos demonstrating naloxone administration, as well as 
counselling skills were considered to be helpful resources. Interviewees said there is a 
need for a PSA protocol or Pharmacy Guild guideline to supplement any training, 
providing a step-by-step guide in when to supply or not to supply OTC naloxone.  
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Discussion  
This mixed-methods study of Australian community pharmacists shows that most 
pharmacists are willing to receive training on the provision of OTC naloxone and opioid 
overdose. Preferences for online and face-to-face training were about equal. Responses 
from pharmacists also indicated that they are largely unaware of existing training 
resources, highlighting the urgent need for widespread education if the potential for 
community pharmacy supplied naloxone is to be realized. This research suggests that 
training around naloxone is not easily accessible for pharmacists. We are aware of an 
online training module offered by the Pharmaceutical Society of Australia, however the 
webinar is only available to members. We are also aware of targeted naloxone training 
programs for health professionals in the state of Victoria. This is particularly important as 
Australian community pharmacists are bound by the Standards for the Provision of 
Pharmacy Medicines and Pharmacist Only Medicines in Community Pharmacy which 
includes the need for “[A]ll staff members who supply Pharmacy Medicines and 
Pharmacist Only Medicines receive initial and ongoing training on products, services, and 
procedures relevant to their supply”.  
In addition, there needs to be a consistent approach to naloxone training (for community 
members and professionals). Education workshops delivered in the United States highlight 
the importance of multi-disciplinary care and emphasize pharmacists’ involvement as part 
of the overall patient care in opioid overdose prevention (16, 17). One strategy would be to 
establish a national program, as has been achieved in Scotland, where training and 
distribution is coordinated across multiple community outlets (e.g., drug user 
organizations, drug treatment services, pharmacists) in order to maximize the reach of 
these initiatives (18).  
Results from this study also suggests that promotion and education are needed to attract 
those pharmacists who are less confident in working with those living with SUD. Those 
already involved with harm reduction on some level (providing OST or stocking naloxone) 
were most interested in further training.  Willingness to attend training was also associated 
with prior post-graduation training in SUD and fewer years of experience. However, 
pharmacists’ confidence in recognizing opioid overdose and supplying naloxone was 
generally low (including among those with prior post-graduation training on SUD and 
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with more years of experience). suggesting that that more general SUD training could be 
updated to include naloxone but also that training efforts on THN need to be widespread. .  
Pharmacists expressed a range of preferences around how they might receive training. 
Professional pharmacy organizations and pharmaceutical companies would be the 
preferred or expected providers of any new educational initiatives. The role of professional 
organizations in leadership and creation of training and guidelines is important in practice 
change in pharmacy (17, 19). Respondents noted the value of a PSA protocol or Guild 
guideline to supplement the training, providing a step-by-step guide in when to supply or 
not to supply OTC naloxone. Pharmacists appeared either unaware, or unable to access, 
existing resources on naloxone potentially because they require membership to 
pharmaceutical societies to retrieve the resources, or because the availability of the 
resources have not been heavily promoted. Visual training aids and counselling skills were 
considered helpful resources. Visual, hands-on training is useful for learning about a drug 
that requires intramuscular administration. A range of resources exist in Australia 
developed by groups other the pharmaceutical industry and related professional 
organizations (20). However, these do not appear to be used as a source of information by 
pharmacists. Further, there may be a need to expand current training resources as recent 
research reviewing the content of naloxone training for pharmacists highlighted the 
importance of educating pharmacists on how to communicate about naloxone with 
patients, in addition to what information should be communicated  (21). In light of low 
uptake of THN from community pharmacies, training that addresses communicate on 
these sensitive issues may be a way to improve naloxone supply in pharmacy practice. We 
note that pharmaceutical companies traditionally address this need. However, with no 
patented naloxone product consistently available at the time of the study, this had not 
occurred. With the emergence of new intranasal naloxone formulations this may change 
(22).  
Time is a common barrier when seeking to train professionals (17, 23-26). Most 
pharmacists preferred a short duration of training - no more than one hour. Accredited 
training that can be counted towards pharmacists’ mandatory training requirements is one 
strategy that may help to overcome time barriers experienced by most pharmacists, since it 
is a professional requirement to allocate time to accredited training. 
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The availability of pharmacist training alone is unlikely to address challenges in expanding 
naloxone supply. The low availability of naloxone (in less than one in four pharmacies 
surveyed) supports that there is enormous potential to increase pharmacy involvement in 
this area. Furthermore, public knowledge of OTC naloxone availability needs to be 
enhanced in order to increase the number of patients requesting the medicine in 
pharmacies. Current research suggests that among people who inject drugs there has been 
an increase in awareness of naloxone (27). However among the other target patient group, 
those prescribed opioids, there is low awareness of naloxone and overdose risks in general 
(28). 
Population level responses are required to reverse the increasing number of opioid 
overdoses. The increasing number of opioid overdoses in Australia include pharmaceutical 
opioids as well as heroin. As the primary distributers of pharmaceutical opioids in our 
communities, pharmacists are increasingly being recognised as potential educators and 
distributers of naloxone (4, 5, 11, 12). The down‐scheduling enables members of the 
public to request naloxone from pharmacies but also for pharmacists to initiate naloxone 
supply. Training and supply issues identified in this study suggests that pharmacists 
require more support if their potential role in overdose prevention is to be realised. 
Limitations 
There are some limitations to consider in interpreting these findings. Not all pharmacists 
responded, though from our random sample, participant demographics represented that 
pharmacists were broadly representative. Females in this sample were slightly 
underrepresented with females representing 61% of registered pharmacists in Australia as 
of September 2015 (22). The distribution of pharmacists by state and age was 
representative of the national distribution (22).  There is the potential for social desirability 
bias relating to self-reported data. To minimize this effect data collection for the online 
survey was anonymous and participants from interviews were informed that their data 
would be de-identified (8, 29).  The question examining further training in substance use 
disorders was limited in that we did not capture details on the extent of the training, or 
when it occurred. Future studies may capture greater detail to allow a more detailed 
examine of this aspect. Further, the qualitative project sample was self-selected and 
findings may not be generalizable across all pharmacists. Finally, the online data were 
collected prior to rescheduling, and the qualitative data were collected after, meaning that 
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those pharmacists in the qualitative study had greater opportunity to hear about naloxone. 
The low knowledge in both samples suggests that this was unlikely to have influenced 
results. 
Conclusion 
Most Australian pharmacists are willing to attend training on opioid overdose and 
naloxone provision. Most pharmacists did not report high levels of confidence in their 
ability to recognize opioid overdose and supply naloxone, irrespective of previous SUD 
training, suggesting there is a need for targeted training on naloxone. Based on the 
preferences of pharmacists, training should be short and offered in a range of modalities 
(online and face-to-face). National pharmacy organizations are ideally placed to provide 
leadership on education. Given the importance of naloxone as one strategy to address 
rising opioid-related mortality, there is an urgent need to better coordinate training and 
delivery of the naloxone. 
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Table 1. Survey participant demographics 
Demographic Frequency (%) N=595 
Gender  
 Male  324 (54.45%) 
 Female 271 (45.55%) 
Age  
 Less than 25 years 26 (4.37%) 
 25-34 years 304 (51.09%) 
 35-54 years 192 (32.27%) 
 55 years and above 73 (12.27%) 
State  
 Victoria 120 (20.17%) 
 Tasmania 16 (2.69%) 
 New South Wales 226 (37.98%) 
 Queensland 110 (18.49%) 
 Northern Territory 5 (0.84%) 
 Western Australia 63 (10.59%) 
 South Australia 45 (7.56%) 
 Australian Capital Territory 10 (1.68%) 
Geographical Location  
 Capital City 247 (41.51%) 
 Other Metropolitan Urban Centre 162 (27.23%) 
 Remote or Rural 186 (31.26%) 
Had received previous training on SUD 288 (48.40%) 
Currently provides OST services 
(methadone, buprenorphine or suboxone 
dispensing) 
307 (51.60%) 
Pharmacy currently stocks naloxone 136 (22.86%) 
Heard of Naloxone being used to reverse 
effects of opioids 425 (71.43%) 
Number of Years in Practicea 9 (5 – 21) 
a
 median and interquartile range presented. SUD=substance use disorder,  
OST=opioid substitution therapy  
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Table 2. Associations with confidence to educate on opioid overdose and naloxone 
administration  
Variable Adjusted Odds Ratio 95% Confidence Interval 
Have received further education about substance use disorders after graduating  
No previous training REF - 
Had previous training 1.14 (0.842 – 1.531) 
Currently providing OST services  
Does not provides OST REF - 
Currently provide OST 1.31 (0.978 – 1.756) 
Gender  
Female REF - 
Male 1.91*** (1.426 – 2.569) 
Year of Practice 
 0.996 (0.983 – 1.009) 
Geographic Location 
Capital City REF - 
Other Metropolitan  0.93 (0.656 – 1.321) 
Rural or Remote 0.88 (0.624 – 1.238) 
Whether the pharmacy stocks naloxone  
Does not stock naloxone REF - 
Currently stocks naloxone 0.985 (0.699 – 1.389) 
*=P<0.05, **=P<0.01, ***=P<0.001, OST=opioid substitution therapy, REF=reference group 
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Table 3. Associations with willingness to educate on opioid overdose and naloxone 
administration  
Variable Adjusted Odds Ratio 95% Confidence Interval 
Have received further education about substance use disorders after graduating  
No previous training REF - 
Had previous training 1.21 (0.783 – 1.869) 
Currently providing OST services  
Does not provides OST REF - 
Currently provide OST 1.65* (1.072 – 2.531) 
Gender  
Female REF - 
Male 1.14 (0.743 – 1.739) 
Year of Practice 
 0.97*** (0.953 – 0.987) 
Geographic Location 
Capital City REF - 
Other Metropolitan  1.18 (0.723 – 1.915) 
Rural or Remote 1.90* (1.120 – 3.224) 
Whether the pharmacy stocks naloxone  
Does not stock naloxone REF - 
Currently stocks naloxone 0.94 (0.571 – 1.565) 
Confidence in ability to educate patients to recognize opioid overdose and safely 
administer naloxone 
 1.45*** (1.263 – 1.670) 
*=P<0.05, **=P<0.01, ***=P<0.001, OST=opioid substitution therapy, REF=reference group 
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Table 4. Associations with willingness to attend training on overdose prevention  
Variable Adjusted Odds Ratio 95% Confidence Interval 
Have received further education about substance use disorders after graduating  
No previous training REF - 
Had previous training 1.94** (1.234 – 3.063) 
Currently providing OST services  
Does not provides OST REF - 
Currently provide OST 1.09 (0.703 – 1.692) 
Gender  
Female REF - 
Male 0.445*** (0.281 – 0.702) 
Year of Practice 
 0.965*** (0.948 – 0.982) 
Geographic Location 
Capital City REF - 
Other Metropolitan  1.22 (0.726 – 2.055) 
Rural or Remote 1.48 (0.881 – 2.500) 
Whether the pharmacy stocks naloxone  
Does not stock naloxone REF - 
Currently stocks naloxone 1.88* (1.069 – 3.296) 
Confidence in ability to educate patients to recognize opioid overdose and safely 
administer naloxone 
 1.31*** (1.136 – 1.505) 
*=P<0.05, **=P<0.01, ***=P<0.001, OST=opioid substitution therapy, REF=reference group 
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Table 5. Distribution of pharmacist’s preferences for mode of delivery and length of 
training 
Mode of Delivery Frequency (%) N=595 Length of Training 
Frequency (%) 
N=595 
Face to Face (one on 
one) 102 (17.14%) Less than 5 minutes 25 (4.20%) 
Face to Face (group) 151 (25.38%) Between 5-15 minutes 182 (30.59%) 
Online 281 (47.23%) Between 16-59 minutes 231 (38.82%) 
Webinar 47 (7.90%) Between 1-2 hours 123 (20.67%) 
Written 6 (1.01%) Up to 4 hours 20 (3.36%) 
Both online and face to 
face 3 (0.50%) More than 4 hours 12 (2.35%) 
Would not like to attend 5 (0.84%)   
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Figure 1a- Recruitment to online survey 
 
Figure 1b – Recruitment to qualitative interviews 
  
1317 pharmacies contacted
1217 pharmacists in charge agreed 
to receive email with study details
595 completed eligible surveys for 
quantitative analysis
595 Pharmacists provided conatct 
information after the survey for 
participation in further research
16 pharmacists responded to 
survey invitation
20 pharmacists contacted via 
professional networks 21 pharmacists interviewed
